GlassScriptPhysician profile
Dawn Hirokawa
NPI 1194927764
$5,548.07
in general payments reported to CMS, 2019-2025
23 companies · $2,062 in 2025
The $2,062 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.78 · 2022: $12.51 · 2023: $1,553 · 2024: $1,903 · 2025: $2,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,139 · Education: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,138.81 |
| Education | $378.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,203.33 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Abbvie INC. | $771.14 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $372.71 | 2023-2025 | |
| Ucb, INC. | $324.25 | 2023-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $306.16 | 2023-2024 | Vtama |
| Amgen INC. | $295.38 | 2023-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $257.41 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $242.50 | 2023-2025 | |
| Incyte Corporation | $237.87 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $231.47 | 2023-2025 | Dupixent, Libtayo |
| Pfizer INC. | $217.44 | 2023-2025 | |
| Organon LLC | $201.08 | 2025 | Vtama |
| Leo Pharma INC. | $182.81 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $175.49 | 2023-2025 | Ilumya, Absorica Ld, Winlevi |
| Arcutis Biotherapeutics, INC. | $170.73 | 2023-2025 | Zoryve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $116.83 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $69.81 | 2024-2025 | Nemluvio, Aklief |
| Genentech USA, INC. | $43.51 | 2024 | Erivedge |
| Botanix Sb INC | $42.22 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $36.67 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.15 | 2024 | Spevigo |
| Strata Skin Sciences, INC. | $15.25 | 2025 | Xtrac |
| Journey Medical Corporation | $13.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Hirokawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.